SCHEMBL16049246

SCHEMBL16049246

COc1nc(SC)ncc1-c1ccc(Oc2ccnc(-c3cnn(C)c3)c2)c(C)n1

nearest known ligand 0.60

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 20/20 0.60
▸ PDGFRA P16234 14/20 0.60
▸ FLT3 P36888 4/20 0.60
▸ PDGFRB P09619 7/20 0.59
▸ KDR P35968 2/20 0.59
▸ CYP2C9 P11712 2/20 0.59
▸ LCK P06239 1/20 0.59
▸ KIT P10721 1/20 0.59
▸ PTK6 Q13882 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30673538 1.00 CSF1R (0.60) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16047987 0.88 CSF1R (0.57) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16046362 0.86 CSF1R (0.67) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16046026 0.86 CSF1R (0.67) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL21824009 0.84 CSF1R (0.58) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16047906 0.84 CSF1R (0.69) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16048363 0.84 CSF1R (0.59) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16046256 0.84 CSF1R (0.69) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16046249 0.84 CSF1R (0.70) CSF1RPDGFRAFLT3PDGFRBKDR
SCHEMBL16046296 0.84 CSF1R (0.68) CSF1RPDGFRAFLT3PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632906-B1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO LTD (CN) 2023-12-13 — — EP disclosed
EP-3632906-B1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO LTD (CN) 2023-12-13 — — EP disclosed
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-09-28 — — US disclosed
CN-107311981-B 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activity 德西费拉制药有限责任公司 2020-05-29 — — CN disclosed
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-28 — — US disclosed
EP-3632906-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
EP-3632906-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
EP-2968286-B1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2017-09-13 — — EP disclosed
EP-2968286-B1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2017-09-13 — — EP disclosed
EP-2968286-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, LLC (US) 2016-01-20 — — EP disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
US-9181223-B2 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-10 — — US disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
WO-2014145025-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed
WO-2014145025-A2 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — WO disclosed
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY FAR1, CSF1R, CSF3R CSF1R 2/4885PDGFRA 977/4885FLT3 209/4885
US-20140275085-A1 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES CSF1R, KIT, CSF3R CSF1R 1/4885PDGFRA 6/4885FLT3 4/4885
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy FAR1, CSF1R, CSF3R CSF1R 2/4885PDGFRA 977/4885FLT3 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback